These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 19880259

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
    Lips I, Dehnad H, Kruger AB, van Moorselaar J, van der Heide U, Battermann J, van Vulpen M.
    Int J Radiat Oncol Biol Phys; 2007 Nov 01; 69(3):656-61. PubMed ID: 17512127
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.
    Int J Radiat Oncol Biol Phys; 2008 Mar 15; 70(4):1124-9. PubMed ID: 18313526
    [Abstract] [Full Text] [Related]

  • 5. Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification.
    Lips IM, van Gils CH, van der Heide UA, Kruger AE, van Vulpen M.
    BJU Int; 2009 Mar 15; 103(6):762-7. PubMed ID: 18990145
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V, De Gersem W, De Neve W, Jacobs F, Lumen N, Vandecasteele K, Villeirs G, De Meerleer G.
    Int J Radiat Oncol Biol Phys; 2009 Nov 15; 75(4):1013-20. PubMed ID: 19386427
    [Abstract] [Full Text] [Related]

  • 8. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.
    J Urol; 2001 Sep 15; 166(3):876-81. PubMed ID: 11490237
    [Abstract] [Full Text] [Related]

  • 9. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H.
    Int J Radiat Oncol Biol Phys; 2008 Jun 01; 71(2):330-7. PubMed ID: 18164858
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Goineau A, Marchand V, Rigaud J, Bourdin S, Rio E, Campion L, Bonnaud-Antignac A, Mahé MA, Supiot S.
    Radiat Oncol; 2013 Mar 06; 8():53. PubMed ID: 23510499
    [Abstract] [Full Text] [Related]

  • 12. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ, Nedelka MA, Arican ZL, Yamada Y, Cohen GN, Shippy AM, Park JJ, Zaider M.
    Brachytherapy; 2008 Mar 06; 7(1):1-6. PubMed ID: 18299108
    [Abstract] [Full Text] [Related]

  • 13. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW, Vora SA, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK.
    Cancer; 2009 Dec 01; 115(23):5596-606. PubMed ID: 19670452
    [Abstract] [Full Text] [Related]

  • 14. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ, Weltman E, Hanriot RM, Luz FP, Cecílio PJ, da Cruz JC, Moreira FR, Santos AS, Martins LC, Nadalin W.
    Radiat Oncol; 2007 Jan 15; 2():6. PubMed ID: 17224072
    [Abstract] [Full Text] [Related]

  • 15. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Keller B, Danjoux C, Szumacher E, Thomas G.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):811-7. PubMed ID: 19836166
    [Abstract] [Full Text] [Related]

  • 16. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
    Coote JH, Wylie JP, Cowan RA, Logue JP, Swindell R, Livsey JE.
    Int J Radiat Oncol Biol Phys; 2009 Jul 15; 74(4):1121-7. PubMed ID: 19131179
    [Abstract] [Full Text] [Related]

  • 17. Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer.
    Namiki S, Ishidoya S, Ito A, Tochigi T, Numata I, Narazaki K, Yamada S, Takai Y, Arai Y.
    Jpn J Clin Oncol; 2009 Nov 15; 39(11):732-8. PubMed ID: 19666904
    [Abstract] [Full Text] [Related]

  • 18. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S, Kim HM, Feng M, Lin A, Tsien C, Elshaikh M, Terrel JE, Murdoch-Kinch C, Eisbruch A.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):725-31. PubMed ID: 16199308
    [Abstract] [Full Text] [Related]

  • 19. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):400-8. PubMed ID: 15667959
    [Abstract] [Full Text] [Related]

  • 20. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S, Saracino B, Petrongari MG, Gomellini S, Marzi S, Landoni V, Gallucci M, Sperduti I, Arcangeli G.
    Radiother Oncol; 2007 Aug 01; 84(2):148-55. PubMed ID: 17692416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.